28328-53-2

Usage

Uses

Used in Pharmaceutical Industry:
BUMETANIDE RELATED COMPOUND B (25 MG) (3-NITRO-4-PHENOXY-5-SULFAMOYLBENZOIC ACID) is used as an intermediate compound for the synthesis of Bumetanide, a potent diuretic medication. It aids in the production of this drug, which is primarily used to treat edema, hypertension, and heart failure by increasing urine output and reducing fluid buildup in the body.
Used in Research and Development:
In the field of research and development, BUMETANIDE RELATED COMPOUND B (25 MG) (3-NITRO-4-PHENOXY-5-SULFAMOYLBENZOIC ACID) is utilized as a key component in the study and development of new diuretic medications and their potential applications. Its unique chemical properties make it a valuable asset in the exploration of novel therapeutic approaches and drug formulations.
Used in Quality Control and Analysis:
BUMETANIDE RELATED COMPOUND B (25 MG) (3-NITRO-4-PHENOXY-5-SULFAMOYLBENZOIC ACID) is also employed in the quality control and analysis of pharmaceutical products, particularly those containing Bumetanide. It helps ensure the purity, potency, and safety of these medications by serving as a reference compound in various analytical techniques, such as high-performance liquid chromatography (HPLC) and mass spectrometry.
Used in the Production of Bumetanide Impurity A (B689550):
BUMETANIDE RELATED COMPOUND B (25 MG) (3-NITRO-4-PHENOXY-5-SULFAMOYLBENZOIC ACID) is used as a starting material in the synthesis of Bumetanide Impurity A (B689550). This impurity is essential for the development and validation of analytical methods, as well as for the assessment of the drug's stability and quality during manufacturing processes.

InChI:InChI=1/C13H10N2O7S/c14-23(20,21)11-7-8(13(16)17)6-10(15(18)19)12(11)22-9-4-2-1-3-5-9/h1-7H,(H,16,17)(H2,14,20,21)

Upstream product

• 61658-43-3 3-nitro-4-phenoxy-5-sulfamoyl-benzoic acid sodium salt 
• 60376-73-0 3-(dimethylaminomethylenesulfamoyl)-5-nitro-4-phenoxybenzoic acid methyl ester 
• 22892-96-2 4-chloro-3-nitro-5-sulfamoylbenzoic acid 
• 108-95-2 phenol 

Downstream Products

• 28395-01-9 5-acetylsulphamyl-3-nitro-4-phenoxy-benzoic acid 
• 61658-50-2 3-nitro-4-phenoxy-5-sulphamyl-benzoyl chloride 
• 28328-54-3 3-amino-5-(aminosulfonyl)-4-phenoxybenzoic acid 
• 57939-04-5 3-nitro-4-phenoxy-5-sulfamoylbenzoic acid methyl ester 
• 1411657-14-1 3-(di(butyl-d9)amino)-4-phenoxy-5-sulfamoylbenzoic acid 
• 1411657-52-7 methyl 3-(di(butyl-d9)amino)-4-phenoxy-5-sulfamoylbenzoate 
• 57939-09-0 4-phenoxy-3-(piperidin-1-yl)-5-sulfamoylbenzoic acid 
• 1431505-42-8 methyl 3-(N-((dimethylamino)methylene)sulfamoyl)-4-phenoxy-5-(piperidin-1-yl)benzoate 
• 1431501-29-9 C₂₂H₂₈N₂O₅S 
• 1357459-06-3 3-(heptan-4-ylamino)-4-phenoxy-5-sulfamoyl-benzoic acid 
• 1357458-81-1 3-dipentylamino-4-phenoxy-5-sulfamoyl-benzoic acid 
• 1357465-05-4 3-(dimethylaminomethylene-sulfamoyl)-5-dipentylamino-4-phenoxy-benzoic acid methyl ester 
• 1357458-70-8 3-(bis(cyclopropylmethyl)amino)-4-phenoxy-5-sulfamoylbenzoic acid 
• 60376-73-0 3-(dimethylaminomethylenesulfamoyl)-5-nitro-4-phenoxybenzoic acid methyl ester 

Relevant academic research and scientific papers

DEUTERATED N-BUTYL BUMETANIDE

The present invention provides a compound of Formula I: as defined herein, or a pharmaceutically acceptable salt thereof.

2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

Compounds are disclosed that have a formula represented by the following:(I) wherein Cy, L1 R1, R2a, R2b, R3, R4, n, and L2 are as described herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, itch, excessive itch, Pruritis, neuropathic pruritis, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

The present invention provides acylsulfonamides including bumetanide derivatives and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these compounds and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl- co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders (autism), bipolar disorder, cancer, the improvement of cognitive function, cognitive impairment, cognitive dysfunction, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, periodic limb movement disorder (PLMD), personality disorders, postherpetic neuralgia, psychosis, restless legs syndrome (RLS), schizophrenia, seizure disorders, spasticity, tinnitus, and withdrawal syndromes.

SUBSTITUTED ANTHRANILIC ACIDS

Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema associated with congestive heart failure, hepatic disease, renal disease including nephrotic syndrome, or clearance of toxic substances from the body.

5-Sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent

5-Sulfamoylbenzoic acids substituted in 4-position by various substituents and in 3-position by a cyclic amino group having sali-diurectic properties, and a process for their manufacture.

3-Amino, 4-thio-substituted, 5-sulphamyl-benzoic acid derivatives

This invention relates to new, therapeutically active compounds of the general formula SPC1 In which A represents one of the groupings EQU1 R2 --O--, R2 --S--, R2 --OS--, and R2 --O2 S--, R1, R2, R3, and R4 each represents hydrogen, an aliphatic radical, a cycloaliphatic radical, or an aromatically, cycloaliphatically, or heterocyclically substituted aliphatic radical, in addition to which R2 and R3 may each represent an aromatic or heterocyclic radical, and when A is EQU2 R1 and R2 may be linked to form a 5- to 8-membered heterocyclic ring system, which may have one or more nitrogen atoms, sulphur atoms, or oxygen atoms in addition to the nitrogen atom linked to R1 and R2 ; R5 is hydrogen or lower alkyl; and R6 is hydrogen or lower alkyl or acyl; to salts, esters, and amides of the said compounds; and to methods for the production of the compounds.